TITLE

Levels of Cholesterol in Small LDL Particles Predict Atherosclerosis Progression and Incident CHD in the HDL-Atherosclerosis Treatment Study (HATS)

AUTHOR(S)
Williams, Paul T.; Zhao, Xue-Qiao; Marcovina, Santica M.; Brown, B. Greg; Krauss, Ronald M.
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: Test whether angiographically-documented changes in percent stenosis and clinical endpoints (coronary-related deaths, myocardial infarctions, stroke, revascularization for worsening ischemia) in the HDL-Atherosclerosis Treatment Study (HATS) were attributable to specific LDL-subclasses. Methods: Gradient gel electrophoresis of on-study LDL-subclass cholesterol concentrations were measured in 32 placebo, 33 simvastatin-niacin, 38 antioxidant, and 39 simvastatin-niacin & antioxidant treated participants. The prespecified primary end point was the mean change per patient from the initial arteriogram to the final arteriogram in the percent stenosis caused by the most severe lesion in each of the nine proximal coronary segments. Results: The change in the percent stenosis of the most severe proximal lesions increased in association with higher concentrations of the small LDL subfractions LDL-IIIb (24.2–24.6 nm) and LDL-IVa (23.3–24.1 nm) before (both P = 0.002) and after (P = 0.01 and P = 0.03 respectively) adjustment for treatment group and on-study HDL-cholesterol, LDL-cholesterol, and triglyceride concentrations. The associations appeared specific to lesions with <30% baseline stenosis. When adjusted for age, sex, baseline BMI and cigarette use, the odds for primary clinical endpoints (death from coronary causes, nonfatal myocardial infarction, stroke, or revascularization for worsening ischemia) were significantly greater in subjects with higher on-study LDL-IIIb levels both before (P = 0.01) and after (P = 0.03) adjustment for treatment group and the standard lipid values. Conclusions: Plasma LDL-IIIb cholesterol concentrations were related to changes in coronary artery stenosis and cardiovascular events in patients with coronary artery disease and low HDL-cholesterol. Trial Registration: ClinicalTrials.gov NCT00000553
ACCESSION #
87624924

 

Related Articles

  • Elevated Cholesterol Increases Risk.  // USA Today Magazine;Feb2000, Vol. 128 Issue 2657, p5 

    Reports the effects of cholesterol levels on stroke risk in the United States. Relationship between apolipoproteins and carotid arteries; Comparison between individuals with ischemic strokes and those without strokes.

  • BIOCHEMICAL ANALYSIS AND APOLIPOPROTEIN E IN HEMORRHAGIC STROKE. M. G., Mazira; K. J., John Tharakan; J. M., Abdullah; Izaini G., Ab Rahman; A. R., Faridah // Malaysian Journal of Medical Sciences;Jan2008 Supplement, p183 

    Introduction: Apolipoprotein E (Apo E), and its respective isoforms, has been linked to outcome and survival following acute central nervous system injury. Apolipoprotein E is a polymorphic glycoprotein produced in different cells that plays a role in cholesterol transport and the mechanisms of...

  • Salusin-β Not Salusin-α Promotes Vascular Inflammation in ApoE-Deficient Mice via the I-κBα/NF-κB Pathway. Zhou, Cheng-Hua; Liu, Lian; Liu, Lu; Zhang, Ming-Xing; Guo, Hao; Pan, Jin; Yin, Xiao-Xing; Ma, Teng-Fei; Wu, Yu-Qing // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Objective: Vascular inflammation plays an important role in the development and progression of atherosclerosis. Recently, salusins (salusin-α and salusin-β) have been reported to be associated wtih atherosclerosis. However, its underlying mechanism remains incompletely known. In this...

  • HDL, Atherosclerosis, and Emerging Therapies. Hafiane, Anouar; Genest, Jacques // Cholesterol;2013, p1 

    This review aims to provide an overview on the properties of high-density lipoproteins (HDLs) and their cardioprotective effects. EmergentHDL therapies will be presented in the context of the current understanding ofHDL function,metabolism, and protective antiatherosclerotic properties. The...

  • Evidence-based optimization of the management of intracranial atherosclerotic disease. Ding, Dale; Starke, Robert // Neurological Sciences;Aug2014, Vol. 35 Issue 8, p1311 

    No abstract available.

  • Acute-Phase-HDL Remodeling by Heparan Sulfate Generates a Novel Lipoprotein with Exceptional Cholesterol Efflux Activity from Macrophages. Shui-Pang Tam; Kisilevsky, Robert; Ancsin, John B. // PLoS ONE;2008, Vol. 3 Issue 12, p1 

    During episodes of acute-inflammation high-density lipoproteins (HDL), the carrier of so-called good cholesterol, experiences a major change in apolipoprotein composition and becomes acute-phase HDL (AP-HDL). This altered, but physiologically important, HDL has an increased binding affinity for...

  • Efficacy study of olmesartan medoxomil on coronary atherosclerosis progression and epicardial adipose tissue volume reduction in patients with coronary atherosclerosis detected by coronary computed tomography angiography: study protocol for a randomized controlled trial. Ying Zhou; Feng Tian; Jing Wang; Jun-Jie Yang; Tao Zhang; Jing Jing; Yun-Dai Chen; Zhou, Ying; Tian, Feng; Wang, Jing; Yang, Jun-Jie; Zhang, Tao; Jing, Jing; Chen, Yun-Dai // Trials;1/6/2016, Vol. 17, p1 

    Background: Epicardial adipose tissue (EAT) is a newly discovered independent risk factor for coronary atherosclerosis. There is a scarcity of information on the reduction of EAT volume to reduce atherosclerosis risk. Coronary computed tomography angiography (CCTA) has emerged as a...

  • Fish eating: why and how of it. Yeolekar, M. E.; Yeolekar, Aditya M. // Indian Journal of Medical Specialities;Jan2011, Vol. 2 Issue 1, p42 

    The concepts in the pathogenesis of atherosclerosis have evolved over time. Cholesterol and lipoprotein components have an established role and effective therapies are available to lower LDL-cholesterol and triglycerides. HDL-cholesterol targeted therapies are few and riddled with side-effects....

  • Associations of apolipoprotein E gene with ischemic stroke and intracranial atherosclerosis. Abboud, Shérine; Viiri, Leena E; Lütjohann, Dieter; Goebeler, Sirkka; Luoto, Teemu; Friedrichs, Silvia; Desfontaines, Philippe; Gazagnes, Marie-dominique; Laloux, Patrice; Peeters, André; Seeldrayers, Pierrette; Lehtimaki, Terho; Karhunen, Pekka; Pandolfo, Massimo; Laaksonen, Reijo // European Journal of Human Genetics;Aug2008, Vol. 16 Issue 8, p955 

    The apolipoprotein E (APOE) ɛ4 allele is associated with elevated cholesterol and risk of atherosclerosis. However, its role in ischemic stroke (IS) remains controversial. We investigated a possible link between IS or the severity of intracranial atherosclerosis and the APOE promoter...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics